Navigation Links
Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
Date:5/22/2008

ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it has created a new proprietary process to develop a vaccine candidate against Severe Acute Respiratory Syndrome (SARS). The company also received renewed research funding from the National Institutes of Health (NIH) to continue preclinical development of SARS vaccine candidates using Novavax's virus-like particle (VLP) technology.

"Until now, it has been difficult to produce VLP vaccine candidates against SARS and other complex infectious disease targets because many of these biological structures do not assemble efficiently," said Dr. Gale Smith, Vice President, Vaccine Development. "Our new proprietary process uses select components of SARS and other structural proteins that combine with cell membranes to form distinctive SARS coronavirus nanoparticles, which are nearly identical to the human SARS virus but lack the genetic material needed to replicate and cause disease."

"This new approach to create VLPs will allow us to continue our work to develop a SARS vaccine candidate and expand the potential applications of our vaccine technology to a broad range of infectious diseases around the world," said Rahul Singhvi, President and Chief Executive Officer of Novavax, Inc.

Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus and was first reported in Asia in February 2003. According to the World Health Organization (WHO), subsequent to the 2003 breakout, over 8,000 people were infected, with 774 reported deaths. While there is currently no known reported SARS transmission globally, WHO and other such agencies continue to monitor the SARS situation on a global basis as health officials remain concerned that SARS or similar disease could reemerge.

The SARS VLP program is conducted under an NIH grant. Novavax does not have the commercial rights to this product candidate.

About Novavax '/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
2. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
3. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
4. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
5. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
6. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
7. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
8. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
9. BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials
10. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
11. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015 "Whether it,s our family, our friends, ... In a single sentence, Dr. Anthony Coyle ... Pfizer,s Centers for Therapeutic Innovation (CTI), sums ... at America,s biopharmaceutical companies. CTI,s unique ... patient foundations and the National Institutes of Health (NIH) ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
(Date:3/26/2015)... , March 26, 2015 When ... by their existing PACS vendor their system would ... determined that they needed a better structured solution ... selected Avreo interWORKS due to its interface capabilities ... meaningful use standards through to the hospital,s radiology ...
Breaking Medicine Technology:Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
... at Food and Drug Administration Meeting , ... WASHINGTON , July 20 ... and treating disease, representatives of the College of American Pathologists (CAP) ... increased oversight of laboratory developed tests (LDTs) and "direct-to-consumer" tests. Most ...
... SHENZHEN, China , July 20 /PRNewswire-Asia-FirstCall/ -- China Nepstar,Chain ... largest,drugstore chain in China based on the number of directly ... card. , , , ... Beginning in May 2010 , Nepstar started to expand its ...
Cached Medicine Technology:CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 2CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 3CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 4China Nepstar Chain Drugstore Provides Updates on Shopper's Card Program 2China Nepstar Chain Drugstore Provides Updates on Shopper's Card Program 3China Nepstar Chain Drugstore Provides Updates on Shopper's Card Program 4
(Date:3/28/2015)... (PRWEB) March 28, 2015 Lately the ... media regarding recent changes and proposals around the NCAA. ... current and former collegiate student-athletes across a spectrum of ... reflect on common challenges. The special panel consists of ... in sports ranging from football, track and field, baseball, ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness ... Chesapeake Conference Center in Chesapeake, Virginia. Each year, ARDX ... women in the Hampton Roads region. The 2015 Women’s ... Women grow stronger through sharing their stories and learning ... the WWC™ theme is T-talk where we will share a ...
(Date:3/27/2015)... 27, 2015 Wellness for Cancer–the first ... criteria for the spa and wellness industry–has certified Hands ... have experienced or are living with cancer. Hands ... 365® Network, will be identified with a special Wellness ... provider of safe, therapeutic services for cancer patients. , ...
(Date:3/27/2015)... City, Mo (PRWEB) March 27, 2015 ... complications for patients undergoing percutaneous coronary intervention (PCI), ... studies have observed a “risk-treatment paradox,” in which ... gain from treatment are treated less often with ... Researchers at Saint Luke’s Mid America Heart Institute ...
(Date:3/27/2015)... 27, 2015 The report “CountryFocus ... an essential source of information on and analysis ... Germany. Germany’s increasingly elderly population and its associated ... market. In 2013, the elderly accounted for 27.1% ... Compound Annual Growth Rate (CAGR) of 1.2% to ...
Breaking Medicine News(10 mins):Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4
... issue of the Journal of Periodontology (JOP) found that smokers ... than non-smokers. , The study followed 10 smokers and 10 ... smoke on the long term outcomes of a treatment to ... teeth. After two years, residual gum recession around the ...
... in APO gene not warranted, researchers say , , TUESDAY, Sept. ... are not as important an indicator of coronary risk as ... previously published studies. , The APO gene comes in three ... gene produce a protein that is an important component of ...
... Sept. 18 Eli Lilly and Company,(NYSE: ... M.D., Ph.D., F.R.C.P.,will join Lilly in January, 2008, ... division responsible for development of Lilly,s,expanding diabetes and ... Tan, Distinguished Medical Fellow, Diabetes and Endocrine, who ...
... 18 Christina Economos, PhD,principal investigator of Shape Up ... to curb childhood obesity, will present,her research at the ... 31st in Boston. "Shape Up Somerville" was a ... third graders in the culturally diverse Boston,suburb of Somerville, ...
... Quality Forum (NQF) and The Joint Commission today announced the,2007 ... Quality,Awards. Honorees were selected in all four award categories., ... ACHIEVEMENT (2 RECIPIENTS), -- Flaura Koplin Winston, M.D., Ph.D. ... Prevention at The Children,s Hospital of Philadelphia and the ...
... today that it has received an award of more ... the Johns Hopkins Institute for Clinical and Translational Research ... Hopkins researchers to hasten and improve the process of ... and eventually to the community. , This grant ...
Cached Medicine News:Health News:Study Downgrades Gene as Heart Risk Factor 2Health News:Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division 2Health News:Success of 'Shape-Up Somerville' Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston 2Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 2Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 3Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 4Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 5Health News:Johns Hopkins receives $100 million grant to speed research from clinic to community 2
... Reposable system components for creating each access port are ... is packaged sterile together with either a 5 mm ... needle is packaged non-sterile; 5 mm, 7/8 mm, ... 5 mm, 7/8 mm, 10 mm and 12 ...
VERSAPORT™ Plus RT Single Use Obturators for use with VERSAPORT™ RT Reusable Cannulae....
The SURGINEEDLE™ is a veress type needle that is used to insufflate the abdomen to create pneumoperitoneum....
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
Medicine Products: